BioLife Solutions (NASDAQ: BLFS) shares preliminary Q4 and 2025 revenue

Rhea-AI Filing Summary

BioLife Solutions, Inc. furnished a current report to disclose that on January 12, 2026 it issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025. The press release is included as Exhibit 99.1, and the company states that this revenue information and the exhibit are being furnished, not filed, so they are not subject to certain liability provisions and are not automatically incorporated into other securities law filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false0000834365Nasdaq00008343652026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

BioLife Solutions, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-36362

94-3076866

(State or other jurisdiction of  incorporation)

(Commission File Number)

(IRS Employer Identification No.)

3303 Monte Villa Parkway,

Bothell, WA 98021

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (425) 402-1400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

			o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol			Name of each exchange on which registered
Common Stock, par value $0.001 per share			BLFS			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition.

On January 12, 2026, the BioLife Solutions, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release of BioLife Solutions, Inc., dated January 12, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			BioLife Solutions, Inc.
Date: January 12, 2026			By:			/s/ Troy Wichterman
						Name: Troy Wichterman
						Title: Chief Financial Officer

FAQ

What did BioLife Solutions (BLFS) report in this 8-K?

BioLife Solutions reported that it issued a press release announcing its preliminary unaudited revenue for the fourth quarter and year ended December 31, 2025.

Which period does BioLife Solutions’ preliminary revenue disclosure cover?

The preliminary unaudited revenue disclosure covers the fourth quarter and the full fiscal year ended December 31, 2025.

How did BioLife Solutions provide the detailed preliminary revenue figures?

The detailed preliminary revenue information is contained in a press release that is attached as Exhibit 99.1.

Is the preliminary revenue information considered filed with the SEC?

No. The company specifies that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liabilities.

What exhibit is included with this BioLife Solutions 8-K?

The 8-K includes Exhibit 99.1, a press release dated January 12, 2026, and Exhibit 104, the cover page interactive data file.

Who signed the BioLife Solutions 8-K regarding preliminary 2025 revenue?

The report was signed on behalf of BioLife Solutions, Inc. by Troy Wichterman, Chief Financial Officer.